We have caught the knife buying RMD for a trade after a 25% collapse in the share price, which, as you can see below, has broken a long-term uptrend. That sell-off came after recent results (August7 2023) which missed sales forecast by 2% and saw margins down 2.1% to 55.8%. Margins were the issue, although they were only 0.3% below expectations. Brokers adjusted numbers downwards after the results to account for narrower margins and higher costs (inflation). Risks include Philips getting back into the market and suggestions that weight loss drugs could take off which would reduce the need for OSA devices.
